These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 579688)

  • 1. Studies on the biochemistry of urokinase.
    Ong EB; Soberano ME; Johnson AJ; Schoellmann G
    Thromb Haemost; 1977 Dec; 38(4):801-8. PubMed ID: 579688
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies on a plasminogen activating system in human milk: IV. Difference in the binding to fibrin between human milk plasminogen activator (mild activator) and urokinase (author's transl)].
    Horie N
    Nihon Ketsueki Gakkai Zasshi; 1979 Oct; 42(5):38-45. PubMed ID: 396753
    [No Abstract]   [Full Text] [Related]  

  • 3. [Purification and characterization of fibrin-binding urokinase (author's transl)].
    Sumi H; Mihara H; Toki N
    Nihon Ketsueki Gakkai Zasshi; 1981 Sep; 44(5):1044-9. PubMed ID: 7036636
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative study of the activity of high and low molecular weight urokinase in the presence of fibrin.
    Samama M; Castel M; Matsuo O; Hoylaerts M; Lijnen HR
    Thromb Haemost; 1982 Feb; 47(1):36-40. PubMed ID: 7041325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.
    Holmberg L; Lecander I; Persson B; Astedt B
    Biochim Biophys Acta; 1978 Nov; 544(1):128-37. PubMed ID: 152655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher fibrin-binding and thrombolytic properties of single polypeptide chain--high molecular weight urokinase.
    Sumi H; Maruyama M; Matsuo O; Mihara H; Toki N
    Thromb Haemost; 1982 Jun; 47(3):297. PubMed ID: 7051412
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of a recombinant chimeric plasminogen activator composed of Gly-Pro-Arg-Pro tetrapeptide and truncated urokinase-type plasminogen activator expressed in Escherichia coli.
    Hua ZC; Chen XC; Dong C; Zhu DX
    Biochem Biophys Res Commun; 1996 May; 222(2):576-83. PubMed ID: 8670247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Blood coagulation mechanism from the viewpoint of molecular biochemistry: Mechanism of fibrinolysis].
    Matsuda T
    Rinsho Byori; 1985 Sep; 33(9):982-8. PubMed ID: 2416968
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.
    Perides G; Noring R; Klempner MS
    Biochem Biophys Res Commun; 1996 Feb; 219(3):690-5. PubMed ID: 8645243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent progress in fibrinolytic mechanism].
    Yasukouchi T
    Rinsho Byori; 1986 Mar; 34(3):235-46. PubMed ID: 3086600
    [No Abstract]   [Full Text] [Related]  

  • 13. Physicochemical properties of highly purified kidney cultured plasminogen activator (single chain urokinase).
    Sumi H; Kosugi T; Matsuo O; Mihara H
    Nihon Ketsueki Gakkai Zasshi; 1982 Feb; 45(1):119-28. PubMed ID: 7051725
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of the plasminogen activator activity units of urinary-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA).
    Creighton-Kempsford LJ; Pring JB; Gaffney PJ
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):481-3. PubMed ID: 1420825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
    Boutaud A; Castellino FJ
    Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids.
    Thorsen S
    Dan Med Bull; 1977 Oct; 24(5):189-206. PubMed ID: 908205
    [No Abstract]   [Full Text] [Related]  

  • 17. Purification of urokinase by a beta-naphthamidine affinity column.
    Astedt B; Holmberg L; Wagner G; Richter P; Ploug J
    Thromb Haemost; 1979 Oct; 42(3):924-8. PubMed ID: 505406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inhibition by plasma of urokinase and tissue activator-induced fibrinolysis in pregnancy and the puerperium.
    Walker JE; Gow L; Campbell DM; Ogston D
    Thromb Haemost; 1983 Feb; 49(1):21-3. PubMed ID: 6221434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of plasminogen activator in human cervical cells.
    Bigbee WL; Jensen RH
    Biochim Biophys Acta; 1978 May; 540(2):285-94. PubMed ID: 656474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine.
    Husain SS; Gurewich V; Lipinski B
    Arch Biochem Biophys; 1983 Jan; 220(1):31-8. PubMed ID: 6338833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.